Date:	2022.	08.10
Your N	ame:	Debin Xu

Manuscript Title: LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the

PI3K/AKT pathway

Manuscript number	(if known)	:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√_None	
4	Consulting fees	√ _None	

		1	
5	lectures, presentations,	_√_None	
	speakers bureaus,		
	manuscript writing or		
_	educational events	/ Name	
6	Payment for expert testimony	_ √ _None	
	testimony		
7	Support for attending	_√_None	
,	meetings and/or travel	_ √ _None	
	meetings and/or traver		
0	Detects along a discount		
8	Patents planned, issued or pending	√ _None	
	pending		
9	Participation on a Data	√ None	
9	Safety Monitoring Board or	_ √ _None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
10	in other board, society,	_	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
10	services		
13	Other financial or non-	_ √ _None	
	financial interests		
DIA	ease summarize the above c	anflict of interest in the fol	lowing hove
PIE	ase suffifialize the above C	ominici of interest in the for	iowing box.

None.			

Date:	2022	.08.10
Date.	2022	.00.10

Your Name: Liangyun Guo

Manuscript Title: LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the

PI3K/AKT pathway

Manuscrip	t number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	_ √ _None	

		1	
5	lectures, presentations,	_√_None	
	speakers bureaus,		
	manuscript writing or		
_	educational events	/ Name	
6	Payment for expert testimony	_ √ _None	
	testimony		
7	Support for attending	_√_None	
,	meetings and/or travel	_ √ _None	
	meetings and/or traver		
0	Detects along a discount		
8	Patents planned, issued or pending	√ _None	
	pending		
9	Participation on a Data	√ None	
9	Safety Monitoring Board or	_ √ _None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
10	in other board, society,	_	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
10	services		
13	Other financial or non-	_ √ _None	
	financial interests		
DIA	ease summarize the above c	anflict of interest in the fol	lowing hove
PIE	ase suffifialize the above C	ominici of interest in the for	iowing box.

None.			

Date:	2022	.08.10
Date:	ZUZZ.	.00.10

Your Name: Shuyong Zhang

Manuscript Title: LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the

PI3K/AKT pathway

Manuscript number	(if known)	:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ √ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	_ √ _None	

		1				
5	Payment or honoraria for lectures, presentations,	_√_None				
	speakers bureaus,					
	manuscript writing or					
_	educational events	/ Name				
6	Payment for expert testimony	_ √ _None				
7	Support for attending	/ Nana				
,	meetings and/or travel	_√_None				
	meetings and/or traver					
0	Detects along a discount					
8	Patents planned, issued or pending	√ _None				
	pending					
9	Double in the control of the control	√ None				
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ √ _None				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√_None				
10		_				
11	Stock or stock options	_√_None				
12	Receipt of equipment,	_√_None				
	materials, drugs, medical writing, gifts or other					
10	services					
13	Other financial or non-	_√_None				
	financial interests					
DIA	assa summariza tha abaya s	anflict of interest in the fol	lowing hove			
PIE	Please summarize the above conflict of interest in the following box:					

None.			

Date:	2022.	08.10
Your N	ame:	Qian Hou

Manuscript Title: LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the

PI3K/AKT pathway

Manuscript number	(if known)	:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ √ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	_ √ _None	

		1				
5	Payment or honoraria for lectures, presentations,	_√_None				
	speakers bureaus,					
	manuscript writing or					
_	educational events	/ Name				
6	Payment for expert testimony	_ √ _None				
7	Support for attending	/ Nana				
,	meetings and/or travel	_√_None				
	meetings and/or traver					
0	Detects along a discount					
8	Patents planned, issued or pending	√ _None				
	pending					
9	Double in the control of the control	√ None				
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ √ _None				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√_None				
10		_				
11	Stock or stock options	_√_None				
12	Receipt of equipment,	_√_None				
	materials, drugs, medical writing, gifts or other					
10	services					
13	Other financial or non-	_√_None				
	financial interests					
DIA	assa summariza tha abaya s	anflict of interest in the fol	lowing hove			
PIE	Please summarize the above conflict of interest in the following box:					

None.			